|Articles|October 5, 2022

SEQSTER and PatientsLikeMe Launch National Rare Disease Study

Study aims to better understand how to reduce delays in diagnosis, decrease disparities in care, and improve outcomes in patients with Alpha-1 Antitrypsin Deficiency.

SEQSTER and PatientsLikeMe (PLM) have collaborated to launch a rare-disease study focused on Alpha-1 Antitrypsin Deficiency (AATD). The study aims to better understand how to reduce delays in diagnosis, decrease disparities in care, and improve outcomes in patients with AATD.

Read more about the study here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

ACT Brief: Policy Shifts, FDA Inspections, and Tariffs Pose New Challenges for Clinical Trials
September 18th 2025
Subcutaneous Saphnelo Shows Positive Phase III Results in Systemic Lupus Erythematosus
September 18th 2025
How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership
September 18th 2025
Viridian Therapeutics Completes Enrollment in Phase III Trial for Novel Monoclonal Antibody in Thyroid Eye Disease
September 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025

Trending on Applied Clinical Trials Online

IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes

Enhancing Clinical Trial Data Accuracy Through the IQVIA and Veeva Partnership

Everything to Know About FDA’s Push Towards Radical Transparency in 2025

Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19

How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran

© 2025 MJH Life Sciences^®

All rights reserved.